HeadOffice@CellsPower.com
+81-3-6403-9242
HeadOffice@CellsPower.com
+81-3-6403-9242

Current “Organic Growth” Business Model

B2B SALES IN SE-ASIA
From 2011-2017, we had a record of 800 stem cell treatments in the countries around our Singapore location. Now, our most popular branch is Vietnam, along with Malaysia, Thailand, Cambodia and Indonesia.

       ⇒ Introducing our product to clinics in SE-Asia through B2B Sales networks
       ⇒ Providing clinics with patients both domestically and internationally

MEDICAL TOURISM ACROSS ASIA
⇒ Providing bone marrow stem cell culture treatment to business elites in Japan through agents in SE-Asia
⇒ Promoting medical tourism business in Vietnam, Thailand, Malaysia, and Indonesia.
⇒ Encouraging stem cell research in local medical schools across the SE-Asia area.
⇒ Bringing SE-Asia clients to Japan for other cellular therapy (Immune Cells, etc.)
⇒ We bring end user from Online marketing to our business partners, and clients

A JAPANESE STEM CELL PRODCUTION & CONSULTING COMPANY
⇒ Working with Japanese Bio-Makers and cells culturing equipment manufacturers to constantly refine our research and production laboratory.
⇒ We introduce clinics, hospitals, researchers, and investors to one another in order to mutually benefit all parties towards the goal of expanding regenerative
    cellular medicine.
⇒ Hosting weekly educational seminars in English and Japanese, which expands or product awareness, and additionally attracts B2B sales agents and B2C
    personal clients.

Current “Organic Growth” Business Model

Competition

Our Strengths

Our Weakness

Solution/Conclusion

Other BM-MSC products
(Ex. TEMCELL)
+ Allogenic (Donor)
+ Larger Quantity
+ Unique Cultivation Methods
+ Transportation  technology
-We follow strict Japanese & International regulations which can be costly and time-consuming
- Other companies already have taken permission for diseases like aGVHD

With our special access to unique restricted Russian research and Japanese equipment technology, Kintaro Cells is the best BM-MSC product on the market. We follow a “branding by sales” method to save time and budget

Adipose (Fat) Stem Cells

+ BM-MSC cells may be more effective at treating diseases

- Adipose Therapy is Cheaper
- Adipose is easier to cultivate
- Adipose is better known

Adipose is more popular for cosmetic therapy, but lacks effect for medical and anti-aging, where we focus our sales.

Umbilical Cord Stem Cells

+ The processing and treatments must be conducted at the birth site, which makes for a very expensive production/treatment cost for umbilical cord compared to Kintaro Cells

- Effects are comparative to BM-MSC therapy.

Ultimately, the cost of umbilical cord treatments outweigh the potential benefits.

IPS Cells

+ Kintaro Cells has greater traction, history, and clinical trials and is currently being used for therapy.

-These cells enable the development of an unlimited source of any type of human cell needed for therapeutic purposes
- Japanese discovered, therefore very popular amongst Japanese.

IPS cells have the potential to be game changers in the field of regenerative medicine, but realistically they are still in too early R&D stages and won’t become practical for treatment for 20+ years. Kintaro Cells is built on 50+ years of Russian research.

Immune Cells

+ Better treatment for general diseases such as diabetes, heart conditions, etc. as well as general anti-aging

- BM-MSC is not effective for cancer treatments

Although still cellular therapy, Immune Cells are not direct competition for Kintaro Cells. Better to work with Immune Cells clinics for co-operation instead of competition

Embryonic Stem Cells

+ Kintaro Cells is a safe therapy.

+ No ethical problems with bone marrow

- Embryonic cells can be manipulated to form many types of adult tissue cells

Due to ethical reason and possibility of teratogenicity (mutations), embryonic stem cells are used mainly in laboratory experiments.

Japan’s PMD Act for quicker Permission for Clinical Trials

In November 2014, in Japan, the Pharmaceuticals, Medical Devices and Other Therapeutic Products Act (PMD Act) took effect. This Act established a pathway for expedited approval in Japan for regenerative medical products. Japan’s new policy requires an early stage clinical trial (i.e. Phase I or small Phase II) at the minimum to confirm safety of the therapy and provide evidence of efficacy. Rather than requiring that the therapy then be evaluated in subsequent trials before making it available to patients, Japan’s new law will allow for a “conditional approval” enabling the product to be brought to market, and for the product to obtain reimbursement in an accelerated manner. Conditional approval does not mean that the regulatory approval process is over. It simply allows the therapy to be made available to patients earlier in the process, and for the sponsor company to begin commercialization and obtain reimbursement.